Next Generation Cardiac Control Monitors Precision of Instrument Testing For Cardiac Events

Annually, approximately 17.9 million lives are lost to Cardiovascular Disease (CVD), accounting for nearly 32% of all global deaths and making CVD the leading cause of death worldwide. The World Health Organization states that 85% of these deaths result from heart attacks and strokes, with half of the victims dying before reaching the hospital. When patients experience chest pain, prompt detection and diagnosis are crucial for making critical treatment decisions. Diagnoses often depend on accurate assessments of specific cardiac markers, which hold significant importance for both patients and care providers in determining the appropriate treatment course. As a result, a generic control may not adequately monitor performance where laboratories need it most, making it essential to select quality control products aimed at medical decision levels suitable for the tested cardiac markers.

Bio-Rad Laboratories (Hercules, CA, USA) has introduced its latest cardiac control product, Cardiac Advance. This next-generation control is designed to monitor instrument testing precision for cardiac events and is optimized with Troponin I and T targets near the limit of instrument detection, in line with the latest guidelines established by the AACC and IFCC. Furthermore, Cardiac Advance control consolidates 10 of the most commonly tested cardiac analytes, such as Troponin, CK-MB, BNP/ProBNP, and Myoglobin.

Bio-Rad's Cardiac Advance control is available in multiple formats, including the standard Liquichek human serum-based control, as well as automation-ready InteliQ and compact vial configurations designed to streamline QC workflows, saving time and resources. Cardiac Advance controls are compatible with Siemens and Roche platforms and are accessible in the US, Europe, and selected Asian markets.

Related Links:
Bio-Rad Laboratories